LYKA LABS
|
The Current P/E Ratio of LYKA LABS is -28.33.
| Share Price | ₹73.5 | Aug 21,2026 |
| Market Cap | ₹265.9 Cr | |
| Earnings-TTM | ₹-9.4 Cr | TTM-Consolidated Results |
| Price/Earnings | -28.33x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of LYKA LABS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹265.9 Cr] as on Aug 21,2026
(/) Earnings [ ₹-9.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -28.33x ]
Thus, for LYKA LABS , the investors are currently willing to pay -28.33 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LYKA LABS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LYKA LABS over the last five years.
Historical PE (Price/Earnings) ratio chart of LYKA LABS
PE Ratio Performance Analysis for LYKA LABS
- LYKA LABS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 10.99x.
- LYKA LABS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LYKA LABS 's p/e ratio peaked in Mar2025 at 44.97x.
- LYKA LABS 's p/e ratio hit its five-year low in Mar2026 of 0x.
How does LYKA LABS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| LYKA LABS | -9.39 | -28.33 | 265.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.47 | 456,090.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 77.60 | 226,976.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.10 | 185,639.0 |
| CIPLA LTD | 3,364.84 | 34.24 | 115,216.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.95 | 98,074.4 |
| MANKIND PHARMA LTD | 2,055.11 | 47.67 | 97,962.6 |
| LUPIN LTD | 5,551.01 | 18.06 | 100,272.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 24.87 | 111,720.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 25.10 | 93,208.3 |
| LAURUS LABS LTD | 1,090.76 | 89.89 | 98,047.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LYKA LABS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -28.33x |
| Max industry PE | 89.89x |
| Median industry PE | 34.24x |
| Average industry PE | 40.33x |
You may also like the below Video Courses